To obtain a compound represented by formula [I] having a protein tyrosine phosphatase IB inhibitory activity and useful as a therapeutic agent for diabetes, diabetic complications and hyperlipemia.
The azole compound is represented by formula [I] {wherein, W is S or O; R is COOR7, X1-A1-COOR7 (R7 is H or an alkyl) or tetrazolyl; R1, R2, R3 and R4 are each H, or the like; A is (CH2)m-X [X is N(R8), C(R9)(R10), CO or CO-N(R8)]; B is an aryl or an aromatic heterocyclic group; R5 is H, or the like; R6 is (Y)s1-(A2)s-Z [Y is O, S(O]4, N(R13), N(R14)-CO, N(R14)-SO2, SO2-N(R14), or the like; A2 is an alkylene; and Z is a cycloalkyl, an aryl, an aromatic heterocyclic group, indanyl or piperazinyl]} or its prodrug or a pharmaceutically acceptable salt thereof.
IKEMOTO TOMOYUKI
SAKATA SHOHEI
MAEKAWA SATOSHI
KASHIWAGI ATSUNORI
